Catalyst Pharmaceuticals Inc. [CPRX] is 12.74% higher this YTD. Is it still time to buy?

Catalyst Pharmaceuticals Inc. [NASDAQ: CPRX] gained 5.86% or 1.16 points to close at $20.97 with a heavy trading volume of 2709556 shares. The company report on December 19, 2022 that Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product.

Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development Strategy Into Synergistic Adjacencies.

It opened the trading session at $19.81, the shares rose to $21.15 and dropped to $19.48, the range by which the price of stock traded the whole day. The daily chart for CPRX points out that the company has recorded 148.75% gains over the past six months. However, it is still -300.19% lower than its most recent low trading price.

If we look at the average trading volume of 2.28M shares, CPRX reached to a volume of 2709556 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Catalyst Pharmaceuticals Inc. [CPRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CPRX shares is $19.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CPRX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Catalyst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 24, 2022. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on September 21, 2018, representing the official price target for Catalyst Pharmaceuticals Inc. stock.

The Average True Range (ATR) for Catalyst Pharmaceuticals Inc. is set at 1.09, with the Price to Sales ratio for CPRX stock in the period of the last 12 months amounting to 10.93. The Price to Book ratio for the last quarter was 8.03, with the Price to Cash per share for the same quarter was set at 2.56.

Trading performance analysis for CPRX stock

Catalyst Pharmaceuticals Inc. [CPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.36. With this latest performance, CPRX shares gained by 20.45% in over the last four-week period, additionally plugging by 148.75% over the last 6 months – not to mention a rise of 228.68% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CPRX stock in for the last two-week period is set at 68.71, with the RSI for the last a single of trading hit 72.95, and the three-weeks RSI is set at 66.27 for Catalyst Pharmaceuticals Inc. [CPRX]. The present Moving Average for the last 50 days of trading for this stock 16.98, while it was recorded at 19.83 for the last single week of trading, and 11.81 for the last 200 days.

Catalyst Pharmaceuticals Inc. [CPRX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Catalyst Pharmaceuticals Inc. [CPRX] shares currently have an operating margin of +37.20 and a Gross Margin at +84.46. Catalyst Pharmaceuticals Inc.’s Net Margin is presently recorded at +28.03.

Return on Equity for this stock inclined to 20.98, with Return on Assets sitting at 18.36.

Catalyst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.20.

An analysis of insider ownership at Catalyst Pharmaceuticals Inc. [CPRX]

There are presently around $1,783 million, or 83.20% of CPRX stock, in the hands of institutional investors. The top three institutional holders of CPRX stocks are: BLACKROCK INC. with ownership of 15,268,931, which is approximately 119.639% of the company’s market cap and around 5.90% of the total institutional ownership; STATE STREET CORP, holding 7,555,423 shares of the stock with an approximate value of $158.44 million in CPRX stocks shares; and VANGUARD GROUP INC, currently with $128.75 million in CPRX stock with ownership of nearly 26.279% of the company’s market capitalization.

Positions in Catalyst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 136 institutional holders increased their position in Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] by around 30,676,232 shares. Additionally, 92 investors decreased positions by around 22,180,622 shares, while 29 investors held positions by with 32,154,888 shares. The mentioned changes placed institutional holdings at 85,011,742 shares, according to the latest SEC report filing. CPRX stock had 63 new institutional investments in for a total of 8,394,371 shares, while 22 institutional investors sold positions of 11,412,651 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here